BioSpace News Archive

Two cohorts have been initiated: a squamous non-small cell lung cancer cohort and a solid tumor “basket” cohort; up to two additional cohorts may be added based on preliminary results

Rocket Pharmaceuticals, Inc. announces it has treated the first patient in the higher dose cohort in its open-label, Phase 1 clinical trial of RP-A501, the Company’s adeno-associated viral vector -based gene therapy for the treatment of Danon Disease.

Organicell Regenerative Medicine, Inc., a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced that the U.S. Food and Drug Administration granted emergency, expanded access approval to treat two mild to moderate COVID-19 patients and one “Long Hauler” post COVID-19 patient.

Metacrine, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies to treat patients with liver and gastrointestinal diseases, today announced the appointments of Catherine Lee as senior vice president, general counsel and Theresa Lowry as vice president, human resources. “We are pleased to welcome Cathy and Theresa to the Metacrine team at this exciting time in the company’s evolution,” sai

Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that management is scheduled to participate in four upcoming virtual investor conferences. Citi’s 15 th Annual BioPharma Virtual Conference on September 9-10, 2020: 1 on 1 investor meetings. H.C. Wainwright 22nd Annual Global Investment Conference: presentation on September 14, 2020 at 12 p.m. ET (

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in two upcoming virtual investor conferences

Bellicum Pharmaceuticals, Inc., a leader in developing novel, controllable cellular immunotherapies for cancers, announced that management will participate in two upcoming virtual investor conferences.

XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present at two upcoming investor conferences: H.C. Wainwright 22 nd Annual Global Investment Conference. The presentation will take place on Monday, September 14, 2020, at 2:00 PM ET. Cantor Fitzgerald Virtual Global Healthcare Conference. The presentation will take place on Tuesday, September 15, 2020, at 4:00 PM ET. Live webcasts of each

Orca Bio and Lyell Immunopharma today announced a research partnership to jointly identify next generation T cell therapies that will combine precision purification T cell technologies from Orca Bio with the scientific expertise in T cell biology from Lyell

Immunovant, Inc. (Nasdaq: IMVT) today announced the pricing of its underwritten public offering of 5,270,093 shares of its common stock at a price to the public of $33.00 per share. The aggregate gross proceeds to Immunovant from the offering are expected to be approximately $173.9 million, before deducting underwriting discounts and commissions and offering expenses. All of the shares of common stock are being offered by Immunovant. The offering is